Figure 6.

Effect of phosphoramidon (PA) on therapeutic efficacy of ¹⁷⁷Lu-JMV4168 to treat subcutaneous PC-3 tumors. Mice were treated with four injections of ¹⁷⁷Lu-JMV4168 (50 MBq, 200 pmol, n=12 per group) or ¹⁷⁵Lu-JMV4168 (200 pmol, n=7 per group) on days 0, 2, 4 and 6, with or without PA. Mean tumor volume with 95% confidence interval (A, C) are displayed for the duration that no data point was missing. Kaplan-Meier survival curves (B, D) are displayed for the event of tumor volume exceeding 1500 mm³. All growth curves of the control mice could be fitted by an exponential growth curve, none should evidence for Gompertzian type of growth. The mean tumor volume doubling time was 11.2 ± 1.2 days. Regrowth of tumors in the treated animals was found after a kick-off time of 32 ± 4 days (¹⁷⁷Lu-JMV4168) and 35 ± 6 days (¹⁷⁷Lu-JMV4168 + PA) and showed comparable regrowth doubling times to the initial and control growth curves. No significant differences in tumor growth and survival were observed for the groups treated with PBS, ¹⁷⁵Lu-JMV4168 or ¹⁷⁵Lu-JMV4168 with PA.